NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

biocryst.com ↗
—
Latest disclosed NPS
no score published
0
NPS entries
0 with a number
60%
Retention
6 May 2026
2021–26
Years covered
7 entries in all

In their words

“Patients who start on ORLADEYO, 60% of them get to a year”
— Charles Gayer, President and CEO, BioCryst Pharmaceuticals, Inc. · Earnings call, Q1 2026 · 6 May 2026
“60% of those patients to stay on therapy through the first year”
— Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q1 2025 · 5 May 2025
“Really strong retention rate for Orladeo patients of 60% in a year. Patients are staying on because they're doing really well.”
— Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q4 2024 · 24 Feb 2025

NPS disclosures (0)

Search the database →

No NPS disclosures yet.

Retention disclosures (7)

Open in the retention database →

6 May 2026
Retention60%

Retention rate (ORLADEYO patients): 60% (Q1 2026) — “Patients who start on ORLADEYO, 60% of them get to a year”

— Charles Gayer, President and CEO, BioCryst Pharmaceuticals, Inc. · Earnings call, Q1 2026 · 6 May 2026
Earnings call, Q1 2026 ↗
5 May 2025
Retention60%

Retention rate (ORLADEYO patients): 60% (Q1 2025) — “60% of those patients to stay on therapy through the first year”

— Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q1 2025 · 5 May 2025
Earnings call, Q1 2025 ↗
24 Feb 2025
Retention60%

Retention rate (Orladeo patients): 60% (1 year) — “really strong retention rate for Orladeo patients of 60% in a year. Patients are staying on because they're doing really well.”

— Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q4 2024 · 24 Feb 2025
Earnings call, Q4 2024 ↗
26 Feb 2024
Retention60%

Retention rate (ORLADEYO patients): 60% (12 months) — “when a patient starts ORLADEYO, we get 60% of those patients to 12 months and then very few discontinuations after that.”

— Charlie Gayer, Senior Vice President, Commercial, BioCryst Pharmaceuticals, Inc. · Earnings call, Q4 2023 · 26 Feb 2024
Earnings call, Q4 2023 ↗
21 Feb 2023
Retention60%

Retention rate: 60% (1 year) — “patient retention, yes, 60% of that 1 year and we would expect – what we are seeing in the overall retention rate is really stabilizing out.”

— BioCryst Pharmaceuticals, Inc. management · Earnings call, Q4 2022 · 21 Feb 2023
Earnings call, Q4 2022 ↗
23 Feb 2022
Retention70%

Retention rate: 70% (FY2021) — “We ended 2021 with an overall patient retention rate of 70%, with patients switching from injectable prophy having particularly strong retention.”

— Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q4 2021 · 23 Feb 2022
Earnings call, Q4 2021 ↗
6 May 2021
Retention75%

Retention rate: 75% (48 weeks (clinical trial)) — “In our clinical trials, this number was about 75% through 48 weeks, telling us that ORLADEYO was well tolerated and is providing outstanding attack control.”

— Anthony Doyle, Chief Financial Officer, BioCryst Pharmaceuticals, Inc. · Earnings call, Q1 2021 · 6 May 2021
Earnings call, Q1 2021 ↗

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.